Ben Lamm on running de-extinction like a platform company
Colossal's CEO reframes de-extinction as the demo for a reusable synthetic-biology platform: AI narrows the genome search, the famous animals fund the research, and the real prize is 'programmable life' across medicine, agriculture, and materials.
Run the Lab Like a Product Company
<strong>A software founder runs a 260-scientist biology lab like a product org</strong> — three disciplines fused into one pipeline, with Jira in place of academic spreadsheets.
we have 260 plus scientists, so like retraining them to work in like Jira and software versus um, you know, just spreadsheets in academia.
De-Extinction Gets the Headlines
<strong>The famous animals are the funnel; the business is a reusable synthetic-biology platform</strong> that also does drug discovery, plastic cleanup, and food security.
But, but, but de-extinction gets the headlines.
The Sum of the Parts
<strong>They don't rebuild a whole genome; they target the conserved regions that drive an animal's core traits</strong> — the parts that make a mammoth read as a mammoth.
the areas of the genome that are conserved that drive the core phenotypes or physical attributes
Decades to Weeks
<strong>Their in-house platform, Genomorph, collapses years of target-hunting into weeks</strong> — narrowing a single dodo genome down to the ~60 genes that drive most of its iconic beak.
9 years, they narrowed down the targets to 300. We've now rerun that same simulation and we could have done that in weeks.
The Win With Zero Headlines
<strong>The same ancient-plus-living DNA analysis produced an mRNA vaccine for elephant herpes</strong> — the top killer of baby elephants — that Lamm says is conferring 100% resistance in testing.
elephant herpes is the number one killer of baby elephants worldwide. Kills more than poaching anything, 20%. So we have now tested successfully an mRNA vaccine in elephants that's conferring 100% resistance to that.
Conservation Alone Isn't Working
<strong>Lamm's bet is to make conservation self-funding</strong> — revenue from the platform's medical and industrial uses underwrites tools he open-sources free to 75 partners, including the IUCN.
conservation's great, but it ain't working.
Programmable Life Is the Prize
<strong>The real prize is 'programmable life' — directed evolution across medicine, agriculture, and materials</strong>, which is why Lamm calls Colossal the most undervalued company on the planet.
we are the most undervalued company on the planet.